PCN197 - COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER IN LEBANON
2018
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI